Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results [Yahoo! Finance]
Kodiak Sciences Inc (KOD)
Last kodiak sciences inc earnings: 11/12 05:30 am
Check Earnings Report
Company Research
Source: Yahoo! Finance
New Phase 3 GLOW2 study of tarcocimab in diabetic retinopathy actively recruiting Phase 1b study of KSI-101 planned for 2Q2024 with the goal of initiating dual pivotal studies in 2024 New Phase 3 DAYBREAK study in wet AMD to include KSI-501 and tarcocimab investigational groups versus aflibercept targeted to start recruitment mid-2024 following completion of FDA discussions Investor day to be scheduled after on-going regulatory interactions completed PALO ALTO, Calif. March 28, 2024 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), today reported business highlights and financial results for the quarter and year ended December 31, 2023 "We intend to progress our portfolio of three late-stage clinical assets as rapidly as we can into Phase 3 value inflection points," said Dr. Victor Perlroth , Chief Executive Officer of Kodiak Sciences. "We were pleased with the Phase 1 study results of KSI-501, our anti-IL-6 and VEGF trap bispecific antibody biopolymer conjugate, in pat
Show less
Read more
Impact Snapshot
Event Time:
KOD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KOD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KOD alerts
High impacting Kodiak Sciences Inc news events
Weekly update
A roundup of the hottest topics
KOD
News
- Will Kodiak Sciences (NASDAQ:KOD) Spend Its Cash Wisely? [Yahoo! Finance]Yahoo! Finance
- Corneal Edema Therapeutics Market to Grow Significantly at a CAGR of 8.54% in the US by 2034 | DelveInsight [Yahoo! Finance]Yahoo! Finance
- Kodiak (KOD) Counts on Tarcocimab Program Despite Setbacks [Yahoo! Finance]Yahoo! Finance
- Kodiak Sciences Inc. (NASDAQ: KOD) had its price target raised by analysts at UBS Group AG from $3.00 to $5.00. They now have a "neutral" rating on the stock.MarketBeat
- Kodiak Sciences Inc. (NASDAQ:KOD) Q4 2023 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
KOD
Earnings
- 3/28/24 - Miss
KOD
Sec Filings
- 4/23/24 - Form ARS
- 4/23/24 - Form DEFA14A
- 4/23/24 - Form DEF
- KOD's page on the SEC website